What is in the CJC-1295 No DAC + Ipamorelin blend?
It combines a GHRH analogue with the ghrelin-receptor agonist Ipamorelin.
Research materialResearch use only
Documentation
Live catalogue
Technical Specifications
A two-component research blend: CJC-1295 No DAC plus Ipamorelin. The Commerce listing determines the actual blend presentation and inventory.
Back to catalogue
Research material
CJC-1295 no DAC + Ipamorelin
CJC-1295 No DAC + Ipamorelin is a defined research blend pairing a growth-hormone-releasing hormone analogue with a ghrelin-receptor agonist. CJC-1295 No DAC is used to examine GHRH receptor signalling without the drug-affinity complex associated with other CJC formats, while Ipamorelin is studied as a growth-hormone secretagogue acting at the growth hormone secretagogue receptor. Together, the blend enables experimental questions about convergent pituitary signalling, ligand selectivity, and temporal patterns in peptide-receptor activation. It is not a single new molecular entity; conclusions should consider the two components independently as well as in combination.
Research highlights
- GHRH receptor signalling; ghrelin-receptor pharmacology; pituitary peptide signalling; neuroendocrine feedback; blend-comparison research.
- This blend is relevant to receptor, cellular, endocrine, and preclinical research. It is for qualified laboratory study only.
Select size / quantity
Select Volume
Live CAD price
$89.99
Selected size
CJC-1295 no DAC + Ipamorelin 10 MGQuantity
1
For research purposes only. Not for human or veterinary use.
Free shipping on orders over $250 CAD
Multi-unit savings: 3 units — 10% off · 5 units — 15% off · 10 units — 20% off. Promotional savings are subject to confirmation at checkout.
Technical Specifications
A two-component research blend: CJC-1295 No DAC plus Ipamorelin. The Commerce listing determines the actual blend presentation and inventory.
Research use only
Materials are intended strictly for laboratory and analytical research.
Contact research supportMechanism & Research Pathways
The two components engage different signalling axes relevant to growth-hormone regulation: GHRH analogues act through the GHRH receptor, whereas Ipamorelin is associated with the ghrelin receptor/GHS-R1a. Both pathways can be investigated in pituitary and neuroendocrine models, but their receptor coupling, feedback regulation, and temporal dynamics are distinct. Research may compare combined versus individual ligands to study pathway interaction, signal amplification hypotheses, or assay-response profiles. Findings from controlled experimental systems do not establish a human-use result and require component-aware interpretation.
Research Context
This blend is relevant to receptor, cellular, endocrine, and preclinical research. It is for qualified laboratory study only.
Frequently Asked Research Questions
Do both components use the same receptor?
No. CJC-1295 No DAC and Ipamorelin are studied through different receptor systems.
Why research a defined blend?
It allows controlled comparison of individual and combined peptide-signalling conditions.